Evidence map›Paper›PMID 32477430›Full record

ArticleDiabetology & metabolic syndrome2020

Association of serum fibroblast growth factor 19 levels with arteriosclerosis parameters assessed by arterial stiffness and atherogenic index of plasma in patients with type 2 diabetes.

Wang-Shu Liu, Meng-Jie Tang, Tian-Li Xu, Jian-Bin Su, Xue-Qin Wang, Feng Xu, Dong-Mei Zhang, Qing Zhu, Jie Cao, Hong Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology & metabolic syndrome, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Wang-Shu Liu *1Department of Endocrinology, Affiliated Hospital 2 of Nantong, University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Meng-Jie Tang *1Department of Endocrinology, Affiliated Hospital 2 of Nantong, University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Tian-Li Xu *2Medical College of Nantong University, No. 19 Qi-xiu Road, Nantong, 226001 China.
Jian-Bin Su1Department of Endocrinology, Affiliated Hospital 2 of Nantong, University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Xue-Qin Wang1Department of Endocrinology, Affiliated Hospital 2 of Nantong, University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Feng Xu1Department of Endocrinology, Affiliated Hospital 2 of Nantong, University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Dong-Mei Zhang3Medical Research Center, Affiliated Hospital 2 of Nantong University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Qing Zhu1Department of Endocrinology, Affiliated Hospital 2 of Nantong, University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Jie Cao1Department of Endocrinology, Affiliated Hospital 2 of Nantong, University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Hong Wang1Department of Endocrinology, Affiliated Hospital 2 of Nantong, University and First People's Hospital of Nantong City, No. 6 North Hai‑er‑xiang Road, Nantong, 226001 China.
Second Affiliated Hospital of Nantong UniversityNantong University · CNAffiliated Hospital of Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of serum fibroblast growth factor 19 (FGF19) in arteriosclerosis is not well known. In the present study, we aimed to explore whether serum FGF19 levels were related to arteriosclerosis parameters, including arterial stiffness and atherogenic index of plasma (AIP), in patients with type 2 diabetes (T2D).

methodsA total of 200 patients with type 2 diabetes and 50 healthy controls were recruited for this study from Apr 2017 to Oct 2018. Serum FGF19 levels, arterial stiffness assessed by brachial ankle pulse wave velocity (baPWV), and AIP assessed by the triglyceride to high-density lipoprotein cholesterol (TG/HDL-c) ratio were measured in those subjects. In addition, other relevant clinical data were also collected.

resultsSerum FGF19 levels in T2D patients were significantly lower than those in healthy controls (

conclusionsThe serum FGF19 levels were independently and inversely associated with baPWV and AIP, which indicate that serum FGF19 may have a protective role in atherosclerosis in patients with T2D.

Indexed as

Atherogenic index of plasmabaPWVFGF19Type 2 diabetes

Identifiers

PMID32477430
PMCPMC7240909
OpenAlexW3030639770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.